Tina Albertson
Chief Medical Officer Caribou Biosciences
Tina is the chief medical officer for Caribou Biosciences and is responsible for strategic leadership of the company’s clinical programs and the clinical, regulatory, and medical affairs functions. Tina brings 15 years of experience leading the development of cellular therapies and biologics. Previously, Tina was chief medical officer and head of development for Lyell Immunopharma, where she built and led the clinical development function and initiated two Phase 1 clinical trials evaluating CAR-T cell and TIL therapies in solid tumors. Prior to Lyell, she was vice president of global drug development at Juno Therapeutics, where she led the global development of BREYANZI (lisocabtagene maraleucel) from preclinical studies to the BLA filing that ultimately led to the initial FDA approval. She previously served as medical director of clinical development and experimental medicine at Seagen (formerly Seattle Genetics). Tina earned her MD from Stanford University and completed a clinical fellowship in pediatric hematology/oncology at Seattle Children’s Hospital and residency in pediatrics at Denver Children’s Hospital. She earned her PhD in cancer biology from the University of Washington and her BS in molecular biology from the University of Oregon.
Seminars
- Exploring multi-edit allogeneic CAR-T engineering strategies, including checkpoint disruption and immune cloaking, designed to enhance persistence and antitumor activity
- Reviewing clinical data supporting durable efficacy, rapid treatment access, and scalable manufacturing across lymphoma and multiple myeloma programs
- Sharing the role of precision genome editing in enabling next-generation off-the-shelf cell therapies with the potential to broaden global patient access
Hear from executive leaders who will discuss their ambitions, strategies and challenges for the future cell and gene therapies, the hottest indications of unmet need and progress towards the next commercial approval, which include:
- What are the future opportunities, promising targets and applications on the horizon for cell and gene therapies to achieve clinical success?
- What are the current industry’s top priorities and upcoming hurdles to development, such as investment, manufacturing, pricing and reimbursement and commercialization to better prepare and strategize to navigate the evolving landscape
- How to structure successful biotech–pharma–academia collaborations in South Korea to balance expectations and maximize the translational speed of your CAR-T, gene editing and therapeutic programs
